Haemonetics wins FDA approval for PerQseal Elite vascular closure system
Haemonetics received FDA approval for its PerQseal Elite system used in large-bore arterial procedures, according to the company's press release.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Haemonetics said the U.S. Food and Drug Administration has approved its PerQseal Elite vascular closure system for large-bore arterial procedures. According to the press release, published by TradingView, the device is used after structural heart and endovascular procedures and leaves nothing permanent in the body.
Dow Jones Newswires reported that the company's shares rose 1.1% to $120.00 in after-hours trading. Haemonetics acquired Vivasure Medical Limited in January 2026, and the system already holds CE Mark approval in Europe.
why it matters
The news mainly concerns Haemonetics and a narrow medical device segment, so it is unlikely to have a broad effect on the wider market.
tags
instruments
sources
- Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System — TradingView, 19 October 2026 at 20:15 UTC
- Haemonetics Gets FDA Approval for Vascular Closure Device — Dow Jones Newswires, 19 October 2026 at 20:53 UTC
- Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System — Reuters, 19 October 2026 at 21:59 UTC
- Haemonetics wins approval of PerQseal Elite vascular closure system — Seeking Alpha, 19 October 2026 at 22:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗